Gene-specific control of the TLR-induced inflammatory response

Clinical Immunology

Volumn 130, Issue 1, 2009, Pages 7-15

  Foster, Simmie L ^a   Medzhitov, Ruslan ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chromatin structure; Gene regulation; Inflammation; Innate immunity; Toll like receptors

Indexed keywords

CHEMOKINE; CYTOKINE; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12P40; PROTEIN P50; SYNAPTOTAGMIN I; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4;

CHROMATIN STRUCTURE; CYTOKINE PRODUCTION; EPIGENETICS; GENE CONTROL; GENE FUNCTION; HUMAN; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR GENE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; INFLAMMATION; TOLL-LIKE RECEPTORS;

EID: 57149107350     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.08.015     Document Type: Review

References (55)

1. Nathan C. Points of control in inflammation. Nature 420 (2002) 846-852
2. Karin M., Lawrence T., and Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124 (2006) 823-835
3. Takeda K., Kaisho T., and Akira S. Toll-like receptors. Annu. Rev. Immunol. 21 (2003) 335-376
4. Yeaman M.R., and Yount N.Y. Unifying themes in host defence effector polypeptides. Nat Rev Microbiol 5 (2007) 727-740
5. Berczi I. Neurohormonal host defense in endotoxin shock. Ann. N. Y. Acad. Sci. 840 (1998) 787-802
6. Lachmann H.J., Goodman H.J., Gilbertson J.A., Gallimore J.R., Sabin C.A., Gillmore J.D., and Hawkins P.N. Natural history and outcome in systemic AA amyloidosis. N. Engl. J. Med. 356 (2007) 2361-2371
7. Hotchkiss R.S., and Karl I.E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348 (2003) 138-150
8. Cunneen J., and Cartwright M. The puzzle of sepsis: fitting the pieces of the inflammatory response with treatment. AACN Clin. Issues 15 (2004) 18-44
9. Cohen J. The immunopathogenesis of sepsis. Nature 420 (2002) 885-891
10. Fujihara M., Muroi M., Tanamoto K., Suzuki T., Azuma H., and Ikeda H. Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol. Ther. 100 (2003) 171-194
11. Nomura F., Akashi S., Sakao Y., Sato S., Kawai T., Matsumoto M., Nakanishi K., Kimoto M., Miyake K., Takeda K., and Akira S. Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J. Immunol. 164 (2000) 3476-3479
12. Liew F.Y., Xu D., Brint E.K., and O'Neill L.A. Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev., Immunol. 5 (2005) 446-458
13. West M.A., and Heagy W. Endotoxin tolerance: a review. Crit. Care Med. 30 (2002) S64-S73
14. Tracey K.J. Physiology and immunology of the cholinergic antiinflammatory pathway. J. Clin. Invest. 117 (2007) 289-296
15. Beeson P.B. Tolerance to bacterial pyrogens. I: Factors influencing its development. J. Exp. Med. 86 (1947) 29-38
16. Beeson P.B. Tolerance to bacterial pyrogens. II: Role of the reticulo-endothelial system. J. Exp. Med. 86 (1947)
17. Cavaillon J.M. The nonspecific nature of endotoxin tolerance. Trends Microbiol. 3 (1995) 320-324
18. Dobrovolskaia M.A., and Vogel S.N. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect. 4 (2002) 903-914
19. Sato S., Takeuchi O., Fujita T., Tomizawa H., Takeda K., and Akira S. A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88-dependent and -independent pathways. Int. Immunol. 14 (2002) 783-791
20. Bohuslav J., Kravchenko V.V., Parry G.C., Erlich J.H., Gerondakis S., Mackman N., and Ulevitch R.J. Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. J. Clin. Invest. 102 (1998) 1645-1652
21. Kastenbauer S., and Ziegler-Heitbrock H.W. NF-kappaB1 (p50) is upregulated in lipopolysaccharide tolerance and can block tumor necrosis factor gene expression. Infect. Immun. 67 (1999) 1553-1559
22. Berg D.J., Kuhn R., Rajewsky K., Muller W., Menon S., Davidson N., Grunig G., and Rennick D. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J. Clin. Invest. 96 (1995) 2339-2347
23. Randow F., Syrbe U., Meisel C., Krausch D., Zuckermann H., Platzer C., and Volk H.D. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J. Exp. Med. 181 (1995) 1887-1892
24. Grutz G. New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J. Leukoc. Biol. 77 (2005) 3-15
25. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 449 (2007) 819-826
26. Chi T. A BAF-centred view of the immune system. Nat. Rev., Immunol. 4 (2004) 965-977
27. Narlikar G.J., Fan H.Y., and Kingston R.E. Cooperation between complexes that regulate chromatin structure and transcription. Cell 108 (2002) 475-487
28. Kurdistani S.K., and Grunstein M. Histone acetylation and deacetylation in yeast. Nat. Rev., Mol. Cell Biol. 4 (2003) 276-284
29. Strahl B.D., and Allis C.D. The language of covalent histone modifications. Nature 403 (2000) 41-45
30. Iizuka M., and Smith M.M. Functional consequences of histone modifications. Curr. Opin. Genet. Dev. 13 (2003) 154-160
31. Ramirez-Carrozzi V.R., Nazarian A.A., Li C.C., Gore S.L., Sridharan R., Imbalzano A.N., and Smale S.T. Selective and antagonistic functions of SWI/SNF and Mi-2beta nucleosome remodeling complexes during an inflammatory response. Genes Dev. 20 (2006) 282-296
32. Saccani S., Pantano S., and Natoli G. Two waves of nuclear factor kappaB recruitment to target promoters. J. Exp. Med. 193 (2001) 1351-1359
33. Saccani S., Pantano S., and Natoli G. Modulation of NF-kappaB activity by exchange of dimers. Mol. Cell 11 (2003) 1563-1574
34. Lomvardas S., and Thanos D. Modifying gene expression programs by altering core promoter chromatin architecture. Cell 110 (2002) 261-271
35. Liu H., Kang H., Liu R., Chen X., and Zhao K. Maximal induction of a subset of interferon target genes requires the chromatin-remodeling activity of the BAF complex. Mol. Cell. Biol. 22 (2002) 6471-6479
36. Agalioti T., Lomvardas S., Parekh B., Yie J., Maniatis T., and Thanos D. Ordered recruitment of chromatin modifying and general transcription factors to the IFN-beta promoter. Cell 103 (2000) 667-678
37. Saccani S., Pantano S., and Natoli G. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat. Immunol. 3 (2002) 69-75
38. Covic M., Hassa P.O., Saccani S., Buerki C., Meier N.I., Lombardi C., Imhof R., Bedford M.T., Natoli G., and Hottiger M.O. Arginine methyltransferase CARM1 is a promoter-specific regulator of NF-kappaB-dependent gene expression. Embo J. 24 (2005) 85-96
39. Kayama H., Ramirez-Carrozzi V.R., Yamamoto M., Mizutani T., Kuwata H., Iba H., Matsumoto M., Honda K., Smale S.T., and Takeda K. Class-specific regulation of pro-inflammatory genes by MyD88 pathways and IkappaBzeta. J. Biol. Chem. 283 (2008) 12468-12477
40. Saccani S., and Natoli G. Dynamic changes in histone H3 Lys 9 methylation occurring at tightly regulated inducible inflammatory genes. Genes Dev. 16 (2002) 2219-2224
41. Brogdon J., Xu Y., Szabo S., An S., Buxton F., Cohen D., and Huang Q. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood (2006)
42. Chan C., Li L., McCall C.E., and Yoza B.K. Endotoxin tolerance disrupts chromatin remodeling and NF-kappaB transactivation at the IL-1beta promoter. J. Immunol. 175 (2005) 461-468
43. Yoza B.K., Hu J.Y., Cousart S.L., Forrest L.M., and McCall C.E. Induction of RelB participates in endotoxin tolerance. J. Immunol. 177 (2006) 4080-4085
44. Foster S.L., Hargreaves D.C., and Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447 (2007) 972-978
45. Kurtz J. Specific memory within innate immune systems. Trends Immunol. 26 (2005) 186-192
46. McCall C.E., and Yoza B.K. Gene silencing in severe systemic inflammation. Am. J. Respir. Crit. Care Med. 175 (2007) 763-767
47. Lehner M.D., Ittner J., Bundschuh D.S., van Rooijen N., Wendel A., and Hartung T. Improved innate immunity of endotoxin-tolerant mice increases resistance to Salmonella enterica serovar typhimurium infection despite attenuated cytokine response. Infect. Immun. 69 (2001) 463-471
48. Rayhane N., Fitting C., Lortholary O., Dromer F., and Cavaillon J.M. Administration of endotoxin associated with lipopolysaccharide tolerance protects mice against fungal infection. Infect. Immun. 68 (2000) 3748-3753
49. Smythies L.E., Sellers M., Clements R.H., Mosteller-Barnum M., Meng G., Benjamin W.H., Orenstein J.M., and Smith P.D. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J. Clin. Invest. 115 (2005) 66-75
50. De Bosscher K., Vanden Berghe W., and Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 24 (2003) 488-522
51. Schleimer R.P. Glucocorticoids suppress inflammation but spare innate immune responses in airway epithelium. Proc. Am. Thorac. Soc. 1 (2004) 222-230
52. Zhang N., Truong-Tran Q.A., Tancowny B., Harris K.E., and Schleimer R.P. Glucocorticoids enhance or spare innate immunity: effects in airway epithelium are mediated by CCAAT/enhancer binding proteins. J. Immunol. 179 (2007) 578-589
53. Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.K., Westin S., Hoffmann A., Subramaniam S., David M., Rosenfeld M.G., and Glass C.K. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122 (2005) 707-721
54. Scott M.G., Dullaghan E., Mookherjee N., Glavas N., Waldbrook M., Thompson A., Wang A., Lee K., Doria S., Hamill P., Yu J.J., Li Y., Donini O., Guarna M.M., Finlay B.B., North J.R., and Hancock R.E. An anti-infective peptide that selectively modulates the innate immune response. Nat. Biotechnol. 25 (2007) 465-472
55. Feldmann M., and Maini R.N. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. 9 (2003) 1245-1250